title: Eribulin for advanced breast cancer: a drug evaluation.
abstract: Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
authors.affiliation: Department of Medical Oncology, Bradford Royal Infirmary, Bradford, UK.
authors.forename: Alaaeldin
authors.initials: A
authors.lastname: Shablak
keywords: Breast neoplasms; Eribulin; Microtubule inhibitor